<?xml version='1.0' encoding='utf-8'?>
<document id="23177284"><sentence text="Management of the transplant recipient with chronic hepatitis C." /><sentence text="More than one-third of listed potential liver recipients in the US are infected with the hepatitis C virus (HCV)" /><sentence text=" Recurrence of infection with HCV after liver transplantation is associated with accelerated graft loss and diminished patient survival" /><sentence text=" Current HCV treatments using peginterferon and ribavirin either alone or with first generation protease inhibitors (telaprevir, boceprevir) are limited by suboptimal viral response, drug-drug interaction, and side effects, some of which may be graft- or life-threatening"><entity charOffset="48-57" id="DDI-PubMed.23177284.s4.e0" text="ribavirin" /><entity charOffset="117-127" id="DDI-PubMed.23177284.s4.e1" text="telaprevir" /><entity charOffset="129-139" id="DDI-PubMed.23177284.s4.e2" text="boceprevir" /><pair ddi="false" e1="DDI-PubMed.23177284.s4.e0" e2="DDI-PubMed.23177284.s4.e0" /><pair ddi="false" e1="DDI-PubMed.23177284.s4.e0" e2="DDI-PubMed.23177284.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23177284.s4.e0" e2="DDI-PubMed.23177284.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23177284.s4.e1" e2="DDI-PubMed.23177284.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23177284.s4.e1" e2="DDI-PubMed.23177284.s4.e2" /></sentence><sentence text=" Rapid advances in new drug therapy for HCV promise to improve outcomes, reduce side effects and drug-drug interaction, shorten treatment duration, and simplify treatment regimens" /><sentence text="" /></document>